{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:01:39Z","timestamp":1777712499228,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Sydney, Robinson Fellowship"},{"name":"Cancer Australia, Priority-driven Collaborative Cancer Research Scheme gran","award":["1129568"],"award-info":[{"award-number":["1129568"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135285"],"award-info":[{"award-number":["1135285"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1150989"],"award-info":[{"award-number":["1150989"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is not known whether there is a survival benefit associated with more frequent surveillance imaging in patients with resected American Joint Committee on Cancer stage III melanoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The aim of this study was to investigate distant disease-free survival (DDFS), melanoma-specific survival (MSS), post distant recurrence MSS (dMSS), and overall survival for patients with resected stage III melanoma undergoing regular computed tomography (CT) or positron emission tomography (PET)\/CT surveillance imaging at different intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>A closely followed longitudinal cohort of patients with resected stage IIIA\u2013D disease treated at a tertiary referral center underwent 3- to 4-monthly, 6-monthly, or 12-monthly surveillance imaging between 2000 and 2017. Survival outcomes were estimated using the Kaplan\u2013Meier method, and log-rank tests assessed the significance of survival differences between imaging frequency groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 473 patients (IIIA, 19%; IIIB, 31%; IIIC, 49%; IIID, 1%) 30% underwent 3- to 4-monthly imaging, 10% underwent 6-monthly imaging, and 60% underwent 12-monthly imaging. After a median follow-up of 6.2 years, distant recurrence was recorded in 252 patients (53%), with 40% detected by surveillance CT or PET\/CT, 43% detected clinically, and 17% with another imaging modality. Median DDFS was 5.1 years (95% confidence interval 3.9\u20136.6). Among 139 IIIC patients who developed distant disease, the median dMSS was 4.4 months shorter in those who underwent 3- to 4-monthly imaging than those who underwent 12-monthly imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Selecting patients at higher risk of distant recurrence for more frequent surveillance imaging yields a higher proportion of imaging-detected distant recurrences but is not associated with improved survival. A randomized comparison of low versus high frequency imaging is needed.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-021-11231-3","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T14:03:29Z","timestamp":1644501809000},"page":"2871-2881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma"],"prefix":"10.1245","volume":"29","author":[{"given":"Mbathio","family":"Dieng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin M.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omgo E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"11231_CR1","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.2009.26.2063","volume":"28","author":"E Romano","year":"2010","unstructured":"Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28:3042\u20137.","journal-title":"J Clin Oncol."},{"key":"11231_CR2","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/annonc\/mdy124","volume":"29","author":"J Lewin","year":"2018","unstructured":"Lewin J, Sayers L, Kee D, et al. Surveillance imaging with FDG-PET\/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018;29:1569\u201374.","journal-title":"Ann Oncol."},{"key":"11231_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.20079","volume":"86","author":"U Leiter","year":"2004","unstructured":"Leiter U, Meier F, Schittek B, et al. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172\u20138.","journal-title":"J Surg Oncol."},{"issue":"6","key":"11231_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1245\/s10434-019-07311-0","volume":"26","author":"AAG Nijhuis","year":"2019","unstructured":"Nijhuis AAG, Dieng M, Khanna N, et al. False-positive results and incidental findings with annual CT or PET\/CT surveillance in asymptomatic patients with resected stage III melanoma. Ann Surg Oncol. 2019;26(6):1860\u20138.","journal-title":"Ann Surg Oncol."},{"key":"11231_CR5","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines): Cutaneous Melanoma. National Comprehensive Cancer Network; 2019."},{"key":"11231_CR6","unstructured":"Cancer Council Australia. Clinical practice guidelines for the diagnosis and management of melanoma. Cancer Council Australia."},{"key":"11231_CR7","unstructured":"The National Institute for Health and Care Excellence (NICE). Melanoma: assessment and management. NICE guidelines [NG14]. NICE; 2015."},{"key":"11231_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2018.11.018","volume":"107","author":"J Larkin","year":"2019","unstructured":"Larkin J, Brown MP, Arance AM, et al. An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. Eur J Cancer. 2019;107:175\u201385.","journal-title":"Eur J Cancer."},{"key":"11231_CR9","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res."},{"key":"11231_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383\u201390.","journal-title":"J Clin Oncol"},{"key":"11231_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med."},{"key":"11231_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med."},{"issue":"11","key":"11231_CR13","doi-asserted-by":"publisher","first-page":"e037857","DOI":"10.1136\/bmjopen-2020-037857","volume":"10","author":"M Dieng","year":"2020","unstructured":"Dieng M, Khanna N, Nguyen MTH, et al. Cost-effectiveness analysis of PET\/ CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open. 2020;10(11):e037857.","journal-title":"BMJ Open."},{"key":"11231_CR14","unstructured":"Australian Institute of Health and Welfare (AIHW). National Death Index (NDI). 2019. Available at: https:\/\/www.aihw.gov.au\/about-our-data\/our-data-collections\/national-death-index."},{"key":"11231_CR15","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392","DOI":"10.3322\/caac.21409"},{"key":"11231_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","volume":"21","author":"C Garbe","year":"2003","unstructured":"Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520\u20139.","journal-title":"J Clin Oncol."},{"key":"11231_CR17","doi-asserted-by":"publisher","first-page":"e000317","DOI":"10.1136\/esmoopen-2017-000317","volume":"3","author":"KHJ Lim","year":"2018","unstructured":"Lim KHJ, Spain L, Barker C, et al. Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO Open. 2018;3:e000317.","journal-title":"ESMO Open."},{"key":"11231_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1245\/s10434-017-5768-8","volume":"24","author":"TS Park","year":"2017","unstructured":"Park TS, Phan GQ, Yang JC, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24:947\u201351.","journal-title":"Ann Surg Oncol."},{"key":"11231_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med."},{"key":"11231_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383:1139\u201348.","journal-title":"N Engl J Med."},{"key":"11231_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017;82:171\u201383.","journal-title":"Eur J Cancer."},{"key":"11231_CR22","first-page":"CD008955","volume":"6","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6:CD008955.","journal-title":"Cochrane Database Syst Rev."},{"key":"11231_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","volume":"103","author":"Y Xing","year":"2011","unstructured":"Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103:129\u201342.","journal-title":"J Natl Cancer Inst."},{"key":"11231_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/aje\/kwn120","volume":"168","author":"SW Duffy","year":"2008","unstructured":"Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98\u2013104.","journal-title":"Am J Epidemiol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-11231-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:22:42Z","timestamp":1649341362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-11231-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["11231"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-11231-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robyn P.M. Saw is supported by MIA and has received honoraria for advisory board participation from MSD, Novartis, and Qbiotics, and speaking honoraria from BMS. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK, and Provectus Inc.; travel support from GSK and Provectus Inc.; and support for conference attendance from Novartis. Alexander M. Menzies reports advisory board fees from BMS, MSD, Novartis, Roche, Pierre-Fabre, and QBiotics. Andrew J. Einstein reports receiving grant funding (paid to Columbia University) for unrelated research, from the National Heart Lung, and Blood Institute, the National Cancer Institute, International Atomic Energy Agency, Canon Medical Systems, GE Healthcare, Roche Diagnostics, and W.L. Gore & Associates; and consulting\/lecturing fees from Ionetix and W.L. Gore & Associates. Mbathio Dieng, Sarah J. Lord, Robin Turner, Omgo E. Nieweg, Louise Emmett, Serigne N. Lo, and Rachael L Morton have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}